Asymchem-Led Group Plans RMB1.24 Billion Capital Increase for AsymBio

Company: AsymBio (Shanghai Asymchem Biotechnology Development) · Event Type: Capital Increase (Proposed) · Deal Value: RMB1.2397 Billion (~$184 Million) · Lead Investor: Asymchem Group · Status: Pending Shareholder Approval Summary AsymBio announced a RMB1.2397 billion capital increase, approximately $184 million, led by parent Asymchem Group…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs
Beeline Therapeutics – $300M Launch
Repligen Buys BioLife for $1.5 Billion
Nurix + Roche; Global BTK Degrader Collaboration